50 Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience

Publication
Article

50 Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience

50 Nipple Sparing Mastectomy With Immediate Lift Using Vertical Technique: Our Initial Experience

Background

Nipple-sparing mastectomy (NSM) is a surgical approach that allows for preservation of the nipple areolar complex (NAC). Patients who have large breasts with moderate to severe ptosis are typically not eligible for NSM secondary to increased risk of complications. We describe a novel technique of NSM using a vertical lift pattern to create a reduced skin envelope for implant- or flap-based reconstruction. Our aim is to study patient characteristics, operating room duration, outcomes, and complications to determine patient selection criteria for this approach.

Methods

We reviewed cases of bilateral vertical lift pattern nipple-sparing mastectomy performed by a single surgeon with immediate implant-based or autologous reconstruction at our institution between June 2022 and April 2023. All patients had greater than size C-cup breasts and/or moderate to severe breast ptosis. In each case, postmastectomy vertical pattern skin reductions were performed, and the NAC was transposed superiorly through a keyhole in the deepithelialized skin flap.


Results

A total of 24 breasts in 12 patients with primary breast cancer underwent bilateral vertical pattern lift NSM with immediate reconstruction. The average age was 49.1 years and average BMI was 33.7 kg/m2. All 12 patients had large, ptotic breasts. Seven patients underwent axillary sentinel lymph node biopsies and 2 patients underwent targeted axillary lymph node dissection. Seven patients underwent direct-to-implant (DTI) reconstruction and 5 patients underwent autologous reconstruction with deep inferior epigastric perforator (DIEP) flaps. For the patients who underwent DTI reconstruction, mean operative time was 3.4 hours and length of stay was 9.8 hours. With autologous reconstruction, mean operative time was 9.9 hours and length of stay was 2.5 days. One patient with BMI 44.3 kg/m2 experienced bilateral mastectomy flap and NAC necrosis requiring revision surgery. Only 2 other patients experienced unilateral partial nipple necrosis, which healed by secondary intention.

Conclusions

At our institution, vertical lift pattern NSM is a relatively safe surgical option for women with larger, ptotic breasts. Skin reduction with deepithelialization and tissue infolding maintains perfusion to promote NAC and skin flap survival with immediate implant- or flap-based reconstruction. Careful selection criteria including BMI, breast size, and degree of breast ptosis should be used when offering this approach to patients to reduce complication risk.

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.